

Brian Kirby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1243167/publications.pdf>

Version: 2024-02-01

95
papers

3,384
citations

172207

29
h-index

155451

55
g-index

96
all docs

96
docs citations

96
times ranked

3679
citing authors

#	ARTICLE	IF	CITATIONS
1	Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial. <i>Dermatology</i> , 2022, 238, 140-147.	0.9	6
2	Cigarette smoking precedes the onset of hidradenitis suppurativa. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	2
3	The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed. <i>British Journal of Dermatology</i> , 2022, 186, 767-768.	1.4	1
4	Dimethyl fumarate modulates the Tregâ€“Th17 cell axis in patients with psoriasis*. <i>British Journal of Dermatology</i> , 2021, 184, 495-503.	1.4	19
5	Recalcitrant dermatitis herpetiformis treated successfully with sulfasalazine. <i>International Journal of Dermatology</i> , 2021, 60, e149-e150.	0.5	0
6	Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial. <i>Dermatology</i> , 2021, 237, 66-69.	0.9	5
7	<i>Mycobacterium bovis</i> BCG Danish Strain 1331 isolated from a periarticular lesion in a domestic cat. <i>Journal of Small Animal Practice</i> , 2021, 62, 924-928.	0.5	1
8	Obstructive sleep apnoea in psoriasis and hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2021, 184, 1183-1185.	1.4	6
9	Biologic survival in hidradenitis suppurativa: much done, more to do. <i>British Journal of Dermatology</i> , 2021, 185, 16-17.	1.4	2
10	Mechanism of action of dimethyl fumarate: a small molecule with big effects. <i>British Journal of Dermatology</i> , 2021, 185, 483-484.	1.4	3
11	Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction?. <i>Experimental Dermatology</i> , 2021, 30, 1554-1568.	1.4	9
12	Metformin use in hidradenitis suppurativa. <i>Journal of Dermatological Treatment</i> , 2020, 31, 261-263.	1.1	36
13	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	0.6	165
14	Secukinumab for patients failing previous tumour necrosis factorâ€“Î± inhibitor therapy: results of a randomized openâ€“label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020, 183, 60-70.	1.4	21
15	Spironolactone therapy for hidradenitis suppurativa. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 464-465.	0.6	12
16	Complementary and alternative medicine use in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 484-485.	1.4	6
17	Remission of severe hidradenitis suppurativa following chemotherapy for Hodgkin lymphoma. <i>British Journal of Dermatology</i> , 2020, 182, 483-484.	1.4	0
18	An audit of pain scores with conventional and white light topical 5â€“methyl aminolaevulinic acid photodynamic therapy for superficial basal cell carcinoma and squamous cell carcinoma in situ. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2020, 36, 161-162.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Enrichment of Plasma Cells in the Peripheral Blood and Skin of Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1091-1094.e2.	0.3	25
20	Comment on "Olmsted Syndrome". <i>Case Reports in Dermatological Medicine</i> , 2020, 2020, 1-2.	0.1	2
21	A new biomarker for psoriatic arthritis?. <i>British Journal of Dermatology</i> , 2020, 183, 805-806.	1.4	1
22	The prevalence of Human polyomavirus 2 (HPyV2) antibody positivity in psoriasis patients. <i>Journal of Clinical Virology</i> , 2020, 127, 104368.	1.6	0
23	Successful treatment of recalcitrant nodular prurigo with tofacitinib. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 918-920.	0.6	17
24	Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 618-619.	0.6	21
25	Dapsone therapy for hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 183, 767-768.	1.4	12
26	Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 239-240.	0.9	3
27	Investigation of the skin microbiome: swabs vs. biopsies. <i>British Journal of Dermatology</i> , 2019, 181, 572-579.	1.4	44
28	Prolonged clindamycin and rifampicin for hidradenitis suppurativa: resist to prevent resistance. <i>British Journal of Dermatology</i> , 2019, 180, 702-703.	1.4	8
29	Understanding the role of cutaneous allergy testing in anogenital dermatoses: a retrospective evaluation of contact sensitization in anogenital dermatoses. <i>International Journal of Dermatology</i> , 2019, 58, 806-810.	0.5	7
30	Obstructive Sleep Apnea Prevalence in an Irish Hidradenitis Suppurativa Cohort. , 2019, , .		0
31	Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization " systematic review and recommendations from the HS ALLIANCE working group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 19-31.	1.3	168
32	Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study. <i>Journal of Clinical Psychology in Medical Settings</i> , 2019, 26, 200-219.	0.8	16
33	Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from <sc>EPIDEPSO</sc>. <i>British Journal of Dermatology</i> , 2019, 180, 397-403.	1.4	16
34	An audit of compliance with tuberculosis screening prior to treatment with biologics in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 611-611.	0.6	1
35	The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health. <i>Dermatology and Therapy</i> , 2018, 8, 33-44.	1.4	14
36	The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS). <i>Dermatology and Therapy</i> , 2018, 8, 45-56.	1.4	21

#	ARTICLE	IF	CITATIONS
37	A re-audit of cervical screening uptake in a dermatology cohort on immunosuppressive medications. <i>British Journal of Dermatology</i> , 2018, 179, 778-779.	1.4	0
38	Primary cutaneous post liver transplant lymphoproliferative disorder (PTLD) successfully treated with radiotherapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 168-169.	1.1	4
39	Adipokines are dysregulated in patients with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2018, 178, 792-793.	1.4	34
40	A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 467-473.	1.3	45
41	Medication adherence among patients with psoriasis on traditional systemic and biologics treatment. <i>British Journal of Dermatology</i> , 2018, 178, e46-e48.	1.4	9
42	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 3-14.	1.3	76
43	Naturally derived Heme-Oxygenase 1 inducers attenuate inflammatory responses in human dendritic cells and T cells: relevance for psoriasis treatment. <i>Scientific Reports</i> , 2018, 8, 10287.	1.6	40
44	Langerhans cells in psoriasis: getting to the core of the disease. <i>British Journal of Dermatology</i> , 2018, 178, 1240-1240.	1.4	12
45	Adipokines and psoriasis: the obesity link. <i>British Journal of Dermatology</i> , 2018, 179, 239.	1.4	4
46	Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. <i>Clinical Immunology</i> , 2017, 177, 43-49.	1.4	26
47	Framingham risk assessment in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2017, 176, 1404-1406.	1.4	8
48	Probing skin physiology through the volatile footprint: Discriminating volatile emissions before and after acute barrier disruption. <i>Experimental Dermatology</i> , 2017, 26, 919-925.	1.4	29
49	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017, 177, 828-836.	1.4	18
50	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , 2017, 176, 1195-1203.	1.4	37
51	The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. <i>British Journal of Dermatology</i> , 2017, 177, 858-859.	1.4	28
52	Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. <i>International Journal of Dermatology</i> , 2017, 56, 1103-1118.	0.5	43
53	AB0755...Depression and anxiety may contribute to higher disease activity and worse quality of life in psoriatic arthritis. , 2017, , .		0
54	Drug survival of methotrexate in psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 345-346.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2389-2395.	0.3	146
56	The relevance of serum vitamin D in psoriasis: a review. <i>Archives of Dermatological Research</i> , 2017, 309, 499-517.	1.1	36
57	Progressive multifocal leucoencephalopathy and psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 271-272.	1.4	1
58	Renal dysfunction in patients taking fumaric acid esters – a retrospective cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 686-691.	1.3	6
59	SAT0467 – All 10-year cardiovascular risk scores are similar in patients with psoriatic arthritis and psoriasis. , 2017, , .		0
60	Worldwide perspective of biosimilars for psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1473-1473.	1.4	1
61	Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 158.	1.6	26
62	FRI0493 – Disease activity together with depression contributes to work disability in psoriatic arthritis. , 2017, , .		0
63	Fatigue as a symptom in psoriasis and psoriatic arthritis: an observational study. <i>British Journal of Dermatology</i> , 2017, 176, 827-828.	1.4	13
64	FRI0507 – The relationship between 10-year cardiovascular risk scores and disease activity in patients with psoriatic arthritis. , 2017, , .		0
65	Is late-onset psoriasis a distinct subtype of chronic plaque psoriasis?. <i>British Journal of Dermatology</i> , 2016, 175, 869-870.	1.4	3
66	Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 29.	0.7	11
67	British Association of Dermatologists – guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. <i>British Journal of Dermatology</i> , 2016, 175, 23-44.	1.4	86
68	Human Î²-Defensin 3 and Its Mouse Ortholog Murine Î²-Defensin 14 Activate Langerhans Cells and Exacerbate Psoriasis-Like Skin Inflammation in Mice. <i>Journal of Investigative Dermatology</i> , 2016, 136, 723-727.	0.3	21
69	The efficacy of PUVA and narrowband UVB phototherapy in the management of generalised granuloma annulare. <i>Journal of Dermatological Treatment</i> , 2016, 27, 136-139.	1.1	11
70	Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2015, 173, 1431-1439.	1.4	220
71	Diagnostic delay in hidradenitis suppurativa is a global problem. <i>British Journal of Dermatology</i> , 2015, 173, 1546-1549.	1.4	261
72	Cervical screening uptake in a dermatology cohort on immunosuppressive agents. <i>British Journal of Dermatology</i> , 2015, 172, 1682-1683.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Drug-induced elastosis perforans serpiginosa. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212482.	0.2	4
74	Obesity-related chronic lymphoedema-like swelling and physical function. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 183-187.	0.2	17
75	Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 978-983.	0.6	155
76	Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities. <i>Dermatologic Clinics</i> , 2015, 33, 41-55.	1.0	138
77	GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report. <i>Journal of Rheumatology</i> , 2014, 41, 1197-1199.	1.0	3
78	Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy. <i>British Journal of Dermatology</i> , 2014, 171, 436-438.	1.4	18
79	Hidradenitis suppurativa: the role of immune dysregulation. <i>International Journal of Dermatology</i> , 2014, 53, 1186-1196.	0.5	90
80	The Use of Transient Elastography and FibroTest for Monitoring Hepatotoxicity in Patients Receiving Methotrexate for Psoriasis. <i>JAMA Dermatology</i> , 2014, 150, 856.	2.0	39
81	Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 305-311.	0.3	30
82	Sitagliptin for severe psoriasis. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 841-842.	0.6	16
83	Drug survival of fumaric acid esters for psoriasis: a retrospective study. <i>British Journal of Dermatology</i> , 2014, 171, 397-402.	1.4	34
84	Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1440-1443.	1.3	45
85	High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 736-740.	0.5	248
86	Alcohol and psoriasis: sobering thoughts. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 819-822.	0.6	36
87	HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. <i>Arthritis and Rheumatism</i> , 2012, 64, 1134-1144.	6.7	187
88	The psych and inflammatory skin disease. <i>British Journal of Dermatology</i> , 2012, 166, 911-911.	1.4	4
89	Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. <i>British Journal of Dermatology</i> , 2011, 164, 1256-1261.	1.4	55
90	Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. <i>Diabetologia</i> , 2011, 54, 2745-2754.	2.9	118

#	ARTICLE	IF	CITATIONS
91	Psoriasis: an opportunity to identify cardiovascular risk. <i>British Journal of Dermatology</i> , 2009, 161, 719-719.	1.4	6
92	Prevalence of psoriasis in patients with alcoholic liver disease. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 698-701.	0.6	33
93	Dermatitis artefacta: an unusual diagnosis in psychodermatology. <i>Irish Journal of Psychological Medicine</i> , 2008, 25, 71-72.	0.7	0
94	Alcohol consumption and psychological distress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2007, 158, 071115063928007-???	1.4	108
95	Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S165-S167.	0.6	54